Goldman Sachs
APYX icon

Goldman Sachs’s Apyx Medical APYX Stock Holding History

Goldman Sachs’s Portfolio APYX Stock Details APYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$199K Sell
44,388
-29,535
-40% -$117K ﹤0.01% 6202
2026
Q1 		$273K Sell
73,923
-18,778
-20% -$70.2K ﹤0.01% 5943
2025
Q4 		$324K Buy
92,701
+74,706
+415% +$261K ﹤0.01% 5829
2025
Q3 		$38.5K Buy
+17,995
New +$38.1K ﹤0.01% 6196
2023
Q2 		– Sell
-18,127
Closed -$52.2K – 5731
2023
Q1 		$52.2K Buy
+18,127
New +$52.9K ﹤0.01% 5545
2022
Q3 		– Sell
-22,241
Closed -$130K – 6242
2022
Q2 		$130K Buy
22,241
+5,580
+33% +$28.6K ﹤0.01% 5781
2022
Q1 		$109K Sell
16,661
-94,058
-85% -$926K ﹤0.01% 6080
2021
Q4 		$1.42M Sell
110,719
-52,489
-32% -$734K ﹤0.01% 4541
2021
Q3 		$2.26M Sell
163,208
-23,631
-13% -$249K ﹤0.01% 4083
2021
Q2 		$1.93M Buy
186,839
+26,002
+16% +$258K ﹤0.01% 4231
2021
Q1 		$1.55M Buy
160,837
+4,484
+3% +$44.9K ﹤0.01% 4242
2020
Q4 		$1.13M Sell
156,353
-15,804
-9% -$105K ﹤0.01% 4123
2020
Q3 		$811K Buy
172,157
+25,370
+17% +$126K ﹤0.01% 4213
2020
Q2 		$815K Buy
146,787
+107,448
+273% +$447K ﹤0.01% 4096
2020
Q1 		$141K Sell
39,339
-173,100
-81% -$1.16M ﹤0.01% 4845
2019
Q4 		$1.8M Buy
212,439
+195,417
+1,148% +$1.41M ﹤0.01% 3721
2019
Q3 		$115K Buy
17,022
+4,480
+36% +$31.8K ﹤0.01% 4945
2019
Q2 		$84K Sell
12,542
-136,577
-92% -$742K ﹤0.01% 4953
2019
Q1 		$941K Buy
+149,119
New +$1.15M ﹤0.01% 4090

Other funds holding APYX

RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
ACM
Archon Capital Management Seattle, Washington $246M AUM 130.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EIM
Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SBCM
Silverberg Bernstein Capital Management Armonk, New York $261M AUM 89.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
HKAM
Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs's APYX Position: Q2 2026 in Review

Goldman Sachs reduced its Apyx Medical (APYX) stake by 40% in Q2 2026, selling an estimated $117K and leaving 44,388 shares worth $199K. The position accounts for ﹤0.01% of the portfolio, ranked #6202.

Goldman Sachs first reported a position in APYX in Q1 2019 and has held it in 19 quarters since. The position peaked at $2.26M in Q3 2021. 68 funds tracked by Wall St. Rank hold APYX as of Q2 2026.

  • Goldman Sachs held 44,388 shares of Apyx Medical worth $199K as of Q2 2026.
  • Goldman Sachs sold 29,535 Apyx Medical shares in Q2 2026, an estimated $117K.
  • Apyx Medical made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6202 holding.
  • Goldman Sachs first reported a position in Apyx Medical in Q1 2019 and has held it in 19 quarters since.
  • Goldman Sachs's Apyx Medical position peaked at $2.26M in Q3 2021.
  • 68 funds tracked by Wall St. Rank held Apyx Medical as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.